OR14-2 Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial

We have previously demonstrated that a 12-week addition of liraglutide to insulin therapy in patients with type 1 diabetes (T1D) results in an improvement in glycemic control, weight loss and a reduction in systolic blood pressure (SBP). We have now conducted a 6 month randomized study investigating...

Descripción completa

Detalles Bibliográficos
Autores principales: Dandona, Paresh, Ghanim, Husam, Hejna, Jeanne, Green, Kelly, Makdissi, Antoine, Borowski, Robert, Kuhadiya, Nitesh, Batra, Manav, Chaudhuri, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555035/
http://dx.doi.org/10.1210/js.2019-OR14-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555035/
http://dx.doi.org/10.1210/js.2019-OR14-2

Ejemplares similares